SCHEMBL24673562

SCHEMBL24673562

CCC(C)(C)OCc1ccc(CN2CCN(CC(C)C)CC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
NPC1 O15118 2/20 0.41
TP53 P04637 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 1/20 0.40
RAB9A P51151 2/20 0.38
POLB P06746 4/20 0.38
PKM P14618 1/20 0.38
ATM Q13315 1/20 0.37
HRH3 Q9Y5N1 3/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
CACNA1G O43497 1/20 0.36
KCNH2 Q12809 1/20 0.36
LMNA P02545 1/20 0.36
USP2 O75604 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23946041 0.89 ALDH1A1 (0.39) ALDH1A1NPC1TP53SMN1; SMN2NPSR1
SCHEMBL23946040 0.87 ALDH1A1 (0.40) ALDH1A1NPC1TP53SMN1; SMN2NPSR1
SCHEMBL23806983 0.80 SMN1; SMN2 (0.46) ALDH1A1NPC1TP53SMN1; SMN2NPSR1
SCHEMBL23945808 0.79 SIGMAR1 (0.46) ALDH1A1NPC1TP53SMN1; SMN2NPSR1
SCHEMBL23945807 0.78 NPC1 (0.42) ALDH1A1NPC1TP53SMN1; SMN2NPSR1
SCHEMBL26080761 0.77 POLB (0.58) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL25479396 0.77 NCF1 (0.46) ALDH1A1KDM4EPOLBATMHRH3
SCHEMBL25701636 0.75 NPC1 (0.41) ALDH1A1NPC1TP53SMN1; SMN2NPSR1
SCHEMBL24800866 0.74 ALDH1A1 (0.47) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL25726124 0.74 KDM4E (0.43) ALDH1A1KDM4EMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885NPC1 3159/4885TP53 1474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.